Adaptive Biotechnologies

129 articles with Adaptive Biotechnologies

• Adaptive Biotech Enters Drug Discovery With Launch of New Company, Adaptive Therapeutics

  8/20/2015

• 23andMe Taps Former Adaptive Biotech Exec as CFO and Head of Ops

  8/17/2015

• Will New CFO Take Adaptive Biotech Public?

  8/11/2015

• Adaptive Biotech Welcomes Chad Cohen As Its New Chief Financial Officer

  8/10/2015

• Adaptive Biotech And Collaborators Demonstrate Importance Of Minimal Residual Disease Measurement In Response Evaluation For Multiple Myeloma

  7/15/2015

• Seattle’s Adaptive Biotech Will Set Up Shop in New York

  7/2/2015

• Adaptive Biotech To Present Data From Largest Study To Date Demonstrating Superior Sensitivity And Prognostic Value Of Next-Generation Sequencing-Based Minimal Residual Disease (MRD) Detection In Pediatric Acute Lymphoblastic Leukemia

  6/12/2015

• Children's Oncology Group/Pediatric Blood And Marrow Transplant Consortium Study Shows Adaptive Biotech' clonoSEQ Minimal Residual Disease (MRD) Test Superior To Flow Cytometry In Predicting Post-Transplant Relapse And Survival In Acute Lymphoblastic Leuk

  6/4/2015

• Here's What Juno Therapeutics Really Thinks About Local Rival Adaptive Biotech

  6/1/2015

• ASCO15: Adaptive Biotech And Collaborators To Present Eight Studies At The 2015 American Society Of Clinical Oncology Annual Meeting Demonstrating The Relevance Of Monitoring Immune Receptors As A New Class Of Biomarkers

  5/29/2015

• Four Seattle Biotech Firms Looking to Hire Hundreds of New Employees

  5/26/2015

• Adaptive Biotech' immunoSEQ Assay Provides Groundbreaking Insight Into T-Cell Fate, Significantly Advancing Understanding Of Adaptive Immunity

  5/12/2015

• Adaptive Biotech And Collaborators To Present 5 Studies Demonstrating Utility Of Immunosequencing To Determine T-Cell Function In Chronic And Infectious Diseases At The 2015 American Association Of Immunologists Annual Meeting

  5/8/2015

• Adaptive Biotech Bags $195 Million In Largest Washington Fundraise This Year

  5/7/2015

• Adaptive Biotechnologies And Researchers From MD Anderson Cancer Center Demonstrate Ability To Detect Hodgkin's Lymphoma In Blood

  4/28/2015

• Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Detects Relapse With Higher Specificity Than PET/CT In Diffuse Large B-Cell Lymphoma Patients

  4/22/2015

• Adaptive Biotechnologies And Collaborators To Present 4 Studies Demonstrating Clinical Relevance Of Immunosequencing In The Treatment Of Solid Tumors At The 2015 American Association for Cancer Research Annual Meeting

  4/15/2015

• Multiple Myeloma Research Foundation (MMRF), University Of Torino, And Adaptive Biotechnologies Work To Speed Novel Minimal Residual Disease Monitoring Technologies To Patients

  4/14/2015

• Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse In Diffuse Large B-Cell Lymphoma Patients By Sensitively Detecting Circulating Tumor DNA

  4/2/2015

• Adaptive Biotechnologies Invited To Present At Upcoming Conferences

  3/17/2015